Lung Cancer News

Tarlatamab showed encouraging response durability among heavily pretreated patients with small cell lung cancer, according to study results.

The addition of serplulimab to chemotherapy extended OS among patients with previously untreated extensive-stage small cell lung cancer, according to randomized phase 3 study results.

Frequent postoperative surveillance imaging after lung cancer resection did not improve outcomes for patients with stage I non-small cell lung cancer, according to data published in Journal of the National Cancer Institute.

An artificial intelligence tool predicted a person’s lung cancer risk after analyzing a single low-dose CT scan, according to study results.

The FDA approved pembrolizumab as adjuvant treatment for patients with stage IB, stage II or stage IIIA non-small cell lung cancer after resection and platinum-based chemotherapy.

Drug-related pneumonitis occurred among 18% of patients receiving osimertinib for advanced epidermal growth factor receptor mutation-positive non-small cell lung cancer, according to study results published in CHEST.

Although use of limited resection or stereotactic body radiation therapy for early-stage non-small cell lung cancer had comparable odds for at least one adverse event, the overall toxicity profiles differed, according to study results.

A preoperative biopsy procedure did not raise the risk for tumor spread through airspaces among patients with resected stage I non-small cell lung cancer, according to a study published in CHEST.

The addition of tumor treating fields to standard therapies significantly improved OS for certain patients with non-small cell lung cancer, according to the therapy’s manufacturer.

A randomized phase 3 trial that evaluated durvalumab vs. chemotherapy for treatment of certain patients with stage IV non-small cell lung cancer failed to meet its primary endpoint of OS, according to the agent’s manufacturer.